Testing Two Drugs to Clear Leftover Cancer Signals After Surgery

This study is testing a treatment called the RELO regimen — a combination of regorafenib and lorigerlimab — in people with colorectal cancer. You would be eligible if you've already finished your standard cancer treatment but have molecular evidence (detected through a special blood test) that some cancer cells may still be present, even though scans don't show visible disease. The goal is to see if this medication combination can clear these lingering cancer signals and prevent the cancer from coming back.

Some colorectal cancer patients finish their standard treatment but have traces of cancer detected only through advanced blood tests, not on regular scans. This trial exists to see whether the medication can eliminate these hidden cancer signals early, before they might develop into visible cancer again, potentially improving survival and preventing recurrence.